TROPION-Lung01 Study Design and Baseline demographics
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously
treated advanced/metastatic (adv/met) non-small cell lung cancer
(NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Myung-Ju Ahn,1,a Aaron Lisberg, 2,a,b Luis Paz-Ares,³ Robin Cornelissen, 4 Nicolas Girard, 5 Elvire Pons-Tostivint, 6 David Vicente Baz, Shunichi Sugawara, Manuel Angel Cobo,⁹
Maurice Pérol, 10 Céline Mascaux, 11 Elena Poddubskaya, 12 Satoru Kitazono, 13
Hidetoshi Hayashi, 14 Jacob Sands, 15 Richard Hall, 16 Yong Zhang, 17 Hong Zebger-Gong, 18 Deise Uema, 17 Isamu Okamoto 19
aEqual contribution as first author. Indicates presenting author.
1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 2David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ³Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit,
Universidad Complutense & CiberOnc, Madrid, Spain; 4Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 5Institut Curie, Paris, France; 6Centre Hospitalier Universitaire de Nantes, Nantes, France; Hospital Universitario
Virgen Macarena, Seville, Spain; 8Sendai Kousei Hospital, Sendai, Japan; FEA Oncología Médica, Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain; 10 Centre Léon
Bérard, Lyon, France; 11Hôpitaux Universitaires de Strasbourg (CHRU), Strasbourg, France; 12Vitamed LLC, Moscow, Russia; 13The Cancer Institute Hospital of JFCR, Tokyo, Japan; 14Kindai University, Osaka, Japan; 15Dana-Farber
Cancer Institute, Boston, MA, USA; 16University of Virginia Health System, Charlottesville, VA, USA; 17Daiichi Sankyo, Inc, Basking Ridge, NJ, USA; 18 Daiichi Sankyo Europe GmbH, Munich, Germany; 19 Kyushu University Hospital,
Fukuoka, Japan
Daiichi-Sankyo
4View entire presentation